ALFA Finder| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 152.2 | 197.9 | 143.8 |
| Other income | 4.1 | 3.0 | 2.7 |
| Total income | 156.3 | 201.0 | 146.5 |
| Profit before exceptional items & tax | 25.9 | 47.3 | 26.2 |
| Exceptional items | 0.0 | -1.0 | 0.0 |
| Profit before tax | 25.9 | 46.3 | 26.2 |
| Net profit | 19.6 | 34.4 | 21.3 |
| Operating margin | 16.6% | 23.0% | 17.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -8.00% |
|---|---|
| Net profit, quarter on quarter | -43.00% |
| Revenue, year on year | +5.80% |
| Operating profit, year on year | -7.20% |
| Operating profit, quarter on quarter | -50.80% |
NSE results filing, NSE: QLINE. Figures extracted from the filing.
Q-Line Biotech Ltd: key numbers
- Share price
- ₹557.00
- Market cap
- ₹1,299 Cr
- Revenue (annual)
- ₹341.7 Cr
- Net profit (annual)
- ₹55.72 Cr
- P/E (TTM)
- 23.3×Sector 54.5×
- Promoter holding
- 67.51%
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Q-Line Biotech Ltd
All →Q-Line Biotech Other Announcement
Q-Line Biotech filed its IPO monitoring agency report for the half year to September 2026. It flags Rs. 0.97 crore of prepayment charges paid from issue proceeds.
Q-Line Biotech Results Update
Q-Line Biotech's H1 FY27 revenue rose 5.83% while EBITDA grew 10.02%, but PAT fell 8.06%. The release also covers a proposed 70% stake acquisition in Heidelco.
Q-Line Biotech Legal & Regulatory
Q-Line Biotech's board said a Rs.10,000 NSE fine for late XBRL voting-results filing was due to a portal glitch and requested a waiver. The total payable including GST is Rs.11,800.
- Value
- ₹0.01 Cr
Q-Line Biotech Board Meeting Date
Q-Line Biotech clarified a clerical error: its board meeting time is 4:15 PM, not 3:00 PM. The November 12, 2026 meeting will consider half-yearly financial results.
Q-Line Biotech Annual General Meeting
Q-Line Biotech Limited held its 16th Annual General Meeting on September 30, 2026. The meeting transacted ordinary and special business, including financial statement adoption and director re-appointments.
Q-Line Biotech Annual General Meeting
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.